Evidence map›Paper›PMID 27330501›Full record

ArticleGastroenterology & hepatology2016

Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients.

Duminda Suraweera, Vinay Sundaram, Sammy Saab

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Gastroenterology & hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Elimination of Hepatitis C in Liver Transplant Recipients.Journal of clinical and translational hepatology · 2018
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Duminda SuraweeraDr Suraweera is a resident in the Department of Medicine at Olive-View Medical Center in Sylmar, California. Dr Sundaram is an assistant professor of medicine at Cedars-Sinai Medical Center in Los Angeles, California. Dr Saab is a professor of medicine and surgery at the University of California at Los Angeles in Los Angeles, California.
Vinay SundaramDr Suraweera is a resident in the Department of Medicine at Olive-View Medical Center in Sylmar, California. Dr Sundaram is an assistant professor of medicine at Cedars-Sinai Medical Center in Los Angeles, California. Dr Saab is a professor of medicine and surgery at the University of California at Los Angeles in Los Angeles, California.
Sammy SaabDr Suraweera is a resident in the Department of Medicine at Olive-View Medical Center in Sylmar, California. Dr Sundaram is an assistant professor of medicine at Cedars-Sinai Medical Center in Los Angeles, California. Dr Saab is a professor of medicine and surgery at the University of California at Los Angeles in Los Angeles, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic hepatitis C virus (HCV) infection is the leading cause of liver transplantation in adults. Although the recurrence of HCV infection after liver transplantation is nearly universal, the recent advances in direct-acting antiviral (DAA) agents have revolutionized the management of HCV infection in the posttransplant setting. A number of these agents have been evaluated in recent clinical trials and have shown high sustained virologic response rates, shorter durations of treatment, and decreased adverse events when compared with the previous treatment of pegylated interferon and ribavirin. This article will review the current literature on the efficacy, tolerability, and potential drug interactions of various DAA agents in patients with recurrent HCV infection posttransplant.

Indexed as

direct-acting antiviral agentsHepatitis C virusliver transplantrecurrenceviral hepatitis

Identifiers

PMID27330501
PMCPMC4865783

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.